Alkem Laboratories (NSE:ALKEM) Total Liabilities : ₹0 Mil (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Alkem Laboratories Total Liabilities?

Alkem Laboratories's Total Liabilities for the quarter that ended in Dec. 2023 was ₹0 Mil.

Alkem Laboratories's quarterly Total Liabilities increased from Jun. 2023 (₹0.00 Mil) to Sep. 2023 (₹47,011.40 Mil) but then declined from Sep. 2023 (₹47,011.40 Mil) to Dec. 2023 (₹0.00 Mil).

Alkem Laboratories's annual Total Liabilities increased from Mar. 2021 (₹39,612.50 Mil) to Mar. 2022 (₹52,218.60 Mil) but then declined from Mar. 2022 (₹52,218.60 Mil) to Mar. 2023 (₹43,216.30 Mil).

Alkem Laboratories Total Liabilities Historical Data

The historical data trend for Alkem Laboratories's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alkem Laboratories Total Liabilities Chart

Alkem Laboratories Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Total Liabilities

Get a 7-Day Free Trial

26,362.40

36,365.70

39,612.50

52,218.60

43,216.30

Alkem Laboratories Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Liabilities	Get a 7-Day Free Trial															-	43,216.30	-	47,011.40	-

Alkem Laboratories Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Alkem Laboratories's Total Liabilities for the fiscal year that ended in Mar. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	37071.5	+	(703.3	+	5441.5
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	43,216

Total Liabilities	=	Total Assets (A: Mar. 2023 )	-	Total Equity (A: Mar. 2023 )
	=	137566.3	-	94350
	=	43,216

Alkem Laboratories's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	0	+	(0	+	0
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	N/A

Total Liabilities	=	Total Assets (Q: Dec. 2023 )	-	Total Equity (Q: Dec. 2023 )
	=	N/A	-	N/A
	=	N/A

Alkem Laboratories Total Liabilities Related Terms

Thank you for viewing the detailed overview of Alkem Laboratories's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Alkem Laboratories (NSE:ALKEM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alkem Laboratories Ltd (NSE:ALKEM) » Definitions » Total Liabilities

Traded in Other Exchanges

539523:India

Address

Senapati Bapat Marg, Alkem House, Devashish Building, Lower Parel, Mumbai, MH, IND, 400 013

Website

https://www.alkemlabs.com

Alkem Laboratories Ltd is an Indian pharmaceutical company engaged in the development, manufacture, and sale of pharmaceutical and nutraceutical products. The company produces branded generics, generic drugs, active pharmaceutical ingredients (APIs) and nutraceuticals in acute and chronic therapeutic areas, such as anti-infective, pain and analgesics, vitamins/minerals/nutrients, cardiac and Diabetology, Gynecology, neuro/central nervous system, dermatology, anti-diabetes, anti-osteoporosis, cardiovascular, and muscle relaxants, which are marketed in Indian and International markets. It operates through the pharmaceutical business segment.

Alkem Laboratories (NSE:ALKEM) Headlines

No Headlines